Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.
Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.
A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.
Change in FACT-O TOI score from baseline to 12 months did not differ significantly between maintenance olaparib and placebo.
Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.
Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian CancerApril 20, 2017
Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.
Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.
A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.
A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.
There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.
Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.
Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.
A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.
An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.
Rucaparib was active with an acceptable safety profile in patients with relapsed, platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations.
Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.
Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.
The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.
NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.
Etoposide was found to damage ovarian tissue in the developing fetus in a study evaluating the effect of the drug on mouse ovarian tissue grown in vitro.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Risk of ovarian cancer is higher in African American women with lower socioeconomic status, the opposite of trends seen in breast cancer.
A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.
Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.
Chronic inactivity has been linked to greater risk for ovarian cancer.
The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.
Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian CancerJune 13, 2016
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|